ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Retrieved on:
Mercoledì, Febbraio 21, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Large intestine, Bangladesh Technical Education Board, Cancer, HNPCC, Medicine, B cell, TTY, DCP, FDA, Safety, Hereditary nonpolyposis colorectal cancer, National Cancer Institute, Vaccine, Risk, Biliary tract, Stomach, Antigen, Ureter, Patient, Pancreas, NK, Clinical trial, Protein, Diagnosis, Translational research, Colorectal cancer, Adenoviridae, Immune system, Brain, Pharmaceutical industry
The study, sponsored by the National Cancer Institute, part of the National Institutes of Health, will include up to 186 participants when fully enrolled and is now open to the randomized controlled portion of the trial.
Key Points:
- The study, sponsored by the National Cancer Institute, part of the National Institutes of Health, will include up to 186 participants when fully enrolled and is now open to the randomized controlled portion of the trial.
- Each of the three vaccines in Tri-Ad5 targets different proteins associated with precancer and cancer cells.
- The vaccine combination is studying whether activation of dendritic cells and training the immune system to recognize those proteins will destroy the precancer cells before the cancer occurs.
- Safety and efficacy of these investigational agents have not been established by any Health Authority, including the FDA.